Oncology

The most read articles in The American Journal of Managed Care's Evidence-Based Oncology ranged from personal narratives to healthcare policy issues that impact the broader population.

This week in managed care, Martin Shkreli, CEO of Turing Pharmaceuticals was arrested on charges of fraud; new research find that drug costs continue to take up a larger share of healthcare spending; and 3 healthcare experts take a look at how to fix the 340B drug pricing program.

Pembrolizumab has been approved as first-line treatment for patients with unresectable or metastatic melanoma.

What we're reading, December 18, 2015: HHS report finds generic drug prices rising faster than inflation; UnitedHealthcare's real-time drug approval tool; and government overcharged by private Medicare Advantage plans.

Results of an analysis of 2012 cancer incidence and survival from various cancer registries, published in CDC's Morbidity and Mortality Weekly Report, indicates reduced incidence of overall cancer across the United States.

Eleven states already ban minors from using tanning beds, and most states have other restrictions such as requiring a parent's permission.

A new report by the Berkeley Research Group provides numbers on Medicare Part B spending by 340B entities, especially for oncology drugs.

A study in the Journal of Clinical Oncology predicts financial stress on Medicare Part D beneficiaries on oral anticancer medicines, even after the expected closing of the donut hole in 2020.

NICE rejects promising oncology agents once again, citing high drug cost.

Several new FDA approvals and research advances in oncology have the potential for improved outcomes among cancer patients.

Updates on screening age recommendations for mammograms, CDC report on a decline in smoking rates in the country, and regulation of laboratory-developed tests.

There are 3 potential solutions for reforming the 340B drug pricing program, according to Michael Kolodziej, MD, national medical director of oncology solutions in the Office of the Chief Medical Officer at Aetna.

A retrospective analysis of phase 1 oncology studies that used biopsy-derived pharmacodynamic biomarkers, could not draw a correlation between subsequent drug development and biopsy sample collection.

While cost is an important component of value, it tells only a small part of the cancer care story. By focusing on issues of payment and cost alone, we miss our opportunity to engage cancer care stakeholders in the process of creating a more effective system of care.

This article describes provider networks and benefit design-including deductibles, cost-sharing, and maximum out-of-pocket limits-for oncology care in 2015 health insurance exchanges.

Depending on one's point of view, the 340B prescription drug program keeps safety net hospitals afloat or serves as a profit center at the expensive of community providers. Three leading voices-Rena M. Conti, PhD; Peter B. Bach, MD, MAPP; and Michael Kolodziej, MD; recommend reforms in the new issue of Evidence-Based Oncology, a publication of The American Journal of Managed Care.

The FDA, today, launched precisionFDA, a cloud-based platform that members can utilize to access and share data sets, analysis pipelines, and bioinformatics tools.

At the first annual conference of the Institute for Clinical Immuno-Oncology on October 1, 2015, in Philadelphia, the discussion revolved around integrating immuno-oncology into clinical practice and programs that assist with patient access to these treatments.

Providers and payers came together to discuss challenges and share success stories as they adapt to the changing healthcare realm.

With the rising costs of cancer care, evidence-based tools can help physicians screen patients for financial toxicity.

The advocacy affiliate of the American Cancer Society, the American Cancer Society Cancer Action Network, is working across the country to pass and implement strong oral chemotherapy fairness laws to help ensure cancer patients have access to the recommended course of treatment without added out-of-pocket costs based on how their drug is administered.

Addressing the financial burden of cancer treatment requires efforts at the policy, payer, and clinic level, and implementation of these strategies, in clinical practice, requires commitment from various stakeholders.

Oral chemotherapy ensured improved quality of life for a young, stage 3 pancreatic cancer patient.

A report by STAT has found that a majority of institutions conducting clinical trials fail to report their results to the website ClinicalTrials.gov.

There is, currently, an unmet need in bladder cancer, a disease expected to be responsible for 16,000 deaths in 2015.